Rituximab combined with EPOCH regimen for treatment of diffuse large B cell lymphoma of the gastrointestinal tract: analysis of 4 cases.
- Author:
Rong-Hua HU
1
;
Wan-Ling SUN
;
Hong ZHAO
;
Wu-Han HUI
;
Yi-Xian GUO
;
Sui-Gui WAN
;
Li SU
Author Information
1. Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.E-mail: hurh@163.com.
- Publication Type:Journal Article
- From:
Journal of Southern Medical University
2016;36(9):1291-1294
- CountryChina
- Language:Chinese
-
Abstract:
We treated 4 with a diagnosis of diffuse large B cell lymphoma involving the gastrointestinal tract with rituximab combined with adjusted dose EPOCH (R-DA-EPOCH) scheme based on a comprehensive analysis of the onset process, clinical and pathological features, and prognosis of the patients, and evaluated their treatment response. Complete remission (CR) was achieved in 3 patients after the treatment and 1 patient with diabetes and hypertension died due to severe infection. R-DA-EPOCH regimen as the first-line treatment of gastrointestinal diffuse large B cell lymphoma has a good short-term efficacy, but its long-term efficacy awaits further evaluation in future studies with larger sample sizes.
